PrimeRFP SCOUT · Federal Contract Recompete Brief

W58P0522F0001Purchase of a TOTAL of 614 — Eli Lilly and Company

Eli Lilly and Company holds $282K across 4 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent W911QY21D0012. PoP ended Feb 15, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

W6qk Acc-Apg Natick

Awarding office

Eli Lilly and Company

Recipient

Feb 15, 2022

PoP end

$1.3B

Obligated

325412

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Eli Lilly and Company — $90

Contract facts

Federal

Contract numberW58P0522F0001

Also listed asW58P05-22-F-0001

Also listed asW911QY21D0012-W58P0522F0001

AgencyW6qk Acc-Apg Natick

Awarding officeW6qk Acc-Apg Natick

IncumbentEli Lilly and Company

UEIUHHVNTY54K68

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVW911QY21D0012

Place of performanceINDIANAPOLIS, IN

PoP end (current)Feb 15, 2022

PoP end (w/ options)Dec 31, 2022

Obligated$1.3B

PURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY. is a federal award for W6qk Acc-Apg Natick held by Eli Lilly and Company. Estimated value $1.3B ($1.3B obligated). Current period of performance ends Feb 15, 2022 (potential Dec 31, 2022). Place of performance: INDIANAPOLIS, IN.

PURCHASE OF A TOTAL OF 614,000 DOSES OF COMBINATION MONOCLONAL ANTIBODY.

Recompete timing

Public

● Past PoP end (1647 days ago)

Current PoP ended Feb 15, 2022 (1647 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Eli Lilly and Company — $282K obligated across 4 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$282K · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C25026N0080

AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN

$230K

Oct 5, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W58P0522F0001?

W58P0522F0001 (Purchase of a TOTAL of 614) is a W6qk Acc-Apg Natick award with an estimated value of $1.3B, currently held by Eli Lilly and Company. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W58P05-22-F-0001?

W58P05-22-F-0001 is the dashed form of PIID W58P0522F0001 (Purchase of a TOTAL of 614), held by Eli Lilly and Company. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W58P0522F0001?

W6qk Acc-Apg Natick awarded W58P0522F0001 to Eli Lilly and Company.

Who is the incumbent on W58P0522F0001?

Eli Lilly and Company is the incumbent with $282K across 4 related awards in SCOUT’s public footprint. The current period of performance ends Feb 15, 2022.

When does Eli Lilly and Company’s W58P0522F0001 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 15, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jan 31, 2023